RT Journal Article SR Electronic T1 Combined therapy of asthma and allergic rhinitis JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP P923 VO 42 IS Suppl 57 A1 Natalia Zhukova A1 Marina Zakharova A1 Olga Kryuchkova YR 2013 UL http://erj.ersjournals.com/content/42/Suppl_57/P923.abstract AB Purpose: To study the clinical efficiency of fluticasone furoate to fluticasone propionate + salmeterol in patients with bronchial asthma (BA), in combination with allergic rhinitis (AR).47 patients with asthma uncontrolled flow in combination with the AR under observation were in 2012. 30 (63.8%) women and 17 (36.2%) of men aged 20 to 53 years, disease duration of 4 to 22 years. BA IV stage was in 15 (31.9%) and III in 32 (68.1%) cases. In 19 (40.4%) cfses with AR combined polypous etmoiditom. Was found allergic to house dust in 32 (68%) patients, pen pads - 27 (57.4%), house dust mite - 22 (46.8%), library dust - 9 (19.1%), animal hair - 13 (27.7%), grass pollen 8 (17%), weed 14 (29.8%), trees, 3 (6.4%). Increased IgE was noted in 39 (83%) patients showed a change spirography indicators of respiratory function grade 1 in 14 (29.8%), grade 2 23 (48.9%), grade 3 10 (21.3%) patients according to FEV1. According to the severity of asthma fluticasone propionate + salmeterol 50/250 or fluticasone propionate + salmeterol 50/500 2 times a day with fluticasone furoate 110 mg were prescribed daily for 8 weeks.Results: All patients reported reduction of symptoms of asthma, rhinitis, full control was achieved in 11 (23.4%) cases, partially controlled for in 36 (76.6%) improved lung function. According rhinoscopy in 15 (31.9%) cases the appearance of polypoid etmoidita was reduced, nasal breathing was fully renewed.Thus, these results show the effectiveness and safety of fluticasone propionate + salmeterol with fluticasone furoate taking in the treatment of asthma, combined with the AR.